Sankala Group’s BioNTech BNTX Stock Holding History

Sankala Group’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$373K	Buy	4,017 +1,323	+49%	+$125K	0.25%	98
2026 Q1	$234K	Buy	2,694 +94	+4%	+$9.66K	0.19%	109
2025 Q4	$287K	Buy	+2,600	New	+$262K	0.23%	97

Other funds holding BNTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

GSK plc London $602M AUM

Sankala Group's BNTX Position: Q2 2026 in Review

Sankala Group increased its BioNTech (BNTX) stake by 49% in Q2 2026, buying an estimated $125K and bringing the position to 4,017 shares worth $373K. The position accounts for 0.25% of the portfolio, ranked #98.

Sankala Group first reported a position in BNTX in Q4 2025 and has held it in 3 quarters since. 282 funds tracked by Wall St. Rank hold BNTX as of Q2 2026.

Sankala Group held 4,017 shares of BioNTech worth $373K as of Q2 2026.
Sankala Group bought 1,323 BioNTech shares in Q2 2026, an estimated $125K.
BioNTech made up 0.25% of Sankala Group's portfolio in Q2 2026, its #98 holding.
Sankala Group first reported a position in BioNTech in Q4 2025 and has held it in 3 quarters since.
282 funds tracked by Wall St. Rank held BioNTech as of Q2 2026.

Based on Sankala Group's 13F filing for Q2 2026, filed 18 Aug 2026.